As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, could not be maintained and therefore was revoked. For the time being, MorphoSys will no longer make a forecast for revenues from product sales, as no such revenues are expected to be realized this year.
As a consequence of the Novartis takeover, MorphoSys is now including the effects from the implementation of the takeover in its guidance. Consequently, the Group now expects R&D expenses of € 205 million to € 225 million for the 2024 which mainly represent our investments in the development of pelabresib and tulmimetostat. Selling, administrative and general expenses are now expected to be between € 260 million and € 270 million.
The overall forecast is subject to a number of uncertainties, including inflation and foreign currency effects.